 HIGH POINT, N.C., Dec. 15, 2020 GLOBE NEWSWIRE -- vTv Therapeutics Inc. Nasdaq: VTVT today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimers disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimers Disease Assessment Scale Cognitive Subscale ADAS-cog14 relative to placebo. The 6-month trial investigated the efficacy and safety of 5 mg azeliragon administered orally once daily compared to placebo in 43 people with mild probable Alzheimers disease and type 2 diabetes. The azeliragon treated group n21 had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo n22 decline of 0.35. These differences were not statistically significant. Consistent with previous studies, azeliragon was generally well-tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups. 